Bayer Announces New Asundexian Stroke Trial Analysis for AHA 2026
- Bayer will present new cardiovascular, kidney and stroke data at the American Heart Association Scientific Sessions in Chicago, November 6-9, 2026.
- A late-breaking presentation will feature an exploratory Phase 3 OCEANIC-STROKE analysis comparing asundexian with placebo, both alongside antiplatelet therapy, for secondary stroke prevention.
- New Kerendia analyses from FINE-HEART and FINEARTS-HF will examine cardiovascular outcomes and kidney-related risk in heart failure.
- Phase 2 CONFIDENCE analyses will evaluate simultaneous finerenone and empagliflozin initiation in adults with chronic kidney disease and type 2 diabetes.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261103288246) on November 03, 2026, and is solely responsible for the information contained therein.